Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma – a preliminary study

References

• Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S, Alitalo K. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res. 1994;54:6571–6577.
   PubMed Web of Science ®Google Scholar
• Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Collan Y, Pyrhonen S. Immunohistochemically detectable Bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology. 2002;62:259–268.
   PubMed Web of Science ®Google Scholar
• John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumour metastasis. Pathol Oncol Res. 2001;7:14–23.
   PubMedGoogle Scholar
• Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157–166.
   PubMed Web of Science ®Google Scholar
• O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006;42:257–267.
   PubMed Web of Science ®Google Scholar
• Anastasov A, Vihinen P, Nikkola J, Pyrhonen S, Vlaykova T. Matrix metalloproteinses in development and progression of skin malignant melanoma. Sci Technol Med. 2011;1:234–241.
   Google Scholar
• Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumour progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109–125.
   PubMed Web of Science ®Google Scholar
• Nikkola J. Integrins and matrix metalloproteinases as prognostic factors in metastatic melanoma [PhD Thesis]. Turku: Turku University; 2004. 128 p.
   Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573.
   PubMed Web of Science ®Google Scholar
• Vlaykova T, Dimov D, Kurzawski M, Wajda A, Lapczuk J, Anastasov A, Drozdzik M. Frequencies of the common promoter polymorphisms in MMP1 and MMP3 genes in a Bulgarian population. Sci Technol Med. 2011;1:55–60.
   Google Scholar
• Zielinnska A, Latocha M, Jurzak M, Kussmierz D. Expression of matrix metalloproteinases and theirs tissue inhibitors in fibroblast cultures and Colo-829 and SH-4 melanoma cultures after photodynamic therapy. In: Davids L, editor. Recent advances in the biology, therapy and management of melanoma. Rijeka: InTech; 2013. p. 1–21.
   Google Scholar
• Vihinen P, Ala-Aho R, Kahari VM. Diagnostic and prognostic role of matrix metalloproteases in cancer. Expert Opin Med Diagn. 2008;2:1025–1039.
   PubMedGoogle Scholar
• Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005;5:203–220.
   PubMed Web of Science ®Google Scholar
• Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40:1362–1378.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen S, Gou WF, Niu ZF, Zhao S, Xiao LJ, Takano Y, Zheng HC. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle. 2013;12:2899–2913.
   PubMed Web of Science ®Google Scholar
• Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803:3–19.
   PubMed Web of Science ®Google Scholar
• Walker RA, Woolley DE. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma. Virchows Arch. 1999;435:574–579.
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanomas: tumour-extracellular matrix interactions in invasion and metastasis. In Vivo. 2001;15:57–64.
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer. 2002;97:432–438.
   PubMed Web of Science ®Google Scholar
• Cotignola J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M, Orlow I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. J Negat Results Biomed. 2007;6:9.
   PubMedGoogle Scholar
• Li X, Qu L, Zhong Y, Zhao Y, Chen H, Daru L. Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:1433–1447.
   PubMed Web of Science ®Google Scholar
• Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, Xiong W, Xu Y, Zhao J. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 2013;517:65–71.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Ishida C, Ikebuchi Y, Mandai M, Mimura K, Murawaki Y, Yuasa I. The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med. 2010;49:887–895.
   PubMed Web of Science ®Google Scholar
• Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, Song X, Jin L, Li G, Zheng H. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One. 2013;8:e62023.
   PubMedGoogle Scholar
• Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012;12:1471–2407.
   Web of Science ®Google Scholar
• Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820–3823.
   PubMed Web of Science ®Google Scholar
• Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–13060.
   PubMed Web of Science ®Google Scholar
• Frohlich E. Proteases in coetaneous malignant melanoma: relevance as biomarker and therapeutic target. Cell Mol Life Sci. 2010;67:3947–3960.
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H, Disci R, Kurul S, Yasasever V, Topuz E. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39–44.
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008; 25:431–436.
   PubMedGoogle Scholar